Privately-held drugmaker EUSA Pharma has announced initial preliminary findings from the SISCO study of siltuximab as a treatment for severe COVID-19.
Interim data from the trial enrolling 21 people show that 16 had either stable or improved disease, while five either had disease worsening or died.
In 2018, the oncology and rare disease specialist bought the global rights to siltuximab, an interleukin (IL)-6 targeted monoclonal antibody, from a subsidiary of Johnson & Johnson (NYSE: JNJ) for $115 million in cash.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze